Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Alligator Bioscience

X
Drug Profile

Research programme: cancer therapeutics - Alligator Bioscience

Alternative Names: ADC-1001; ADC-1001-RA; ADC-1004; ADC-1004-CHIPS; ADC-1012; ADC-1014; ADC-CHIPS; FIND-1001; FIND-1004; TNFR-SF + ND - bispecific antibody; TNFR-SF - monospecific antibody

Latest Information Update: 21 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alligator Bioscience
  • Class Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Bispecific antibodies; Monoclonal antibodies; Proteins
  • Mechanism of Action Complement C5a inhibitors; Interleukin 1 receptor antagonists; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Inflammation

Highest Development Phases

  • No development reported Diabetes mellitus; Gout; Inflammation; Juvenile rheumatoid arthritis; Rheumatoid arthritis
  • Discontinued Reperfusion injury

Most Recent Events

  • 21 Dec 2021 No development reported - Preclinical for Diabetes mellitus in Sweden (SC) as of December 2021 (Alligator Bioscience pipeline, December 2021)
  • 21 Dec 2021 No development reported - Preclinical for Gout in Sweden (SC) as of December 2021 (Alligator Bioscience pipeline, December 2021)
  • 21 Dec 2021 No development reported - Preclinical for Inflammation in Sweden (Parenteral) as of December 2021 (Alligator Bioscience pipeline, December 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top